Alis Biosciences’ plan is a familiar tactic in the private equity world, but the firm will instead be listed on the public ...

BML Capital Management, an activist investor that owns 9.9% of Elevation’s shares, is urging the company to wind down ...

Losing the FDA’s senior negotiators would slow the renewal of the user fee programs “considerably,” according to policy and ...

Industry representatives will still be allowed at these meetings, but they will no longer have a spot on the advisory ...

Like they say about the weather in Iceland, if you don’t like an action taken by the new administration, wait five minutes; ...

Despite these cuts, the FDA should be able to stay above a "trigger" level that would prevent it from collecting fees from ...

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

With tariffs pushing manufacturing home to the U.S., Pitchbook warns of reduced M&A activity and venture capital funding.

Kennedy is planning modifications to the Vaccines Adverse Event Reporting System to identify whether vaccines contribute to ...

GeoVax was using its HHS contract to develop its next-generation multi-antigen COVID-19 vaccine, which is in Phase IIb ...

During the first quarter, 22 rounds of biopharma layoffs in California affected about 995 employees total, while 17 rounds in ...